The Patent Finder

Nouscom AG

6 patents currently held · Updated Nov 18, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
Aug 2038
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Aug 27, 2027
    The maintenance fee for Compositition and uses of teleost invariant chain to enhance T cell response to a vaccine (US 11,912,743) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 20, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 6 of 6

PatentTitleStatus Expires Confidence
US 11,098,324Non Human Great Apes Adenovirus Nucleic Acid- and Amino Acid-Sequences, Vectors Containing Same, and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 11,578,109A Universal Vaccine Based on Shared Tumor Neoantigens for Prevention and Treatment of Micro Satellite Instable (MSI) Cancers
In force
 · High confidence
In forceHigh confidence
US 11,912,743Compositition and uses of teleost invariant chain to enhance T cell response to a vaccine
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,643,666Eukaryotic Cell Line
In force
 · High confidence
In forceHigh confidence
US 12,576,143Teleost Invariant Chain Cancer Vaccine
In force
 · High confidence
In forceHigh confidence
US 12,749,556Selection of Cancer Mutations for Generation of a Personalized Cancer Vaccine
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 6: 1 patent in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 1 abandoned · 1 no status recorded

Showing 1 to 4 of 4, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/729,271Recombinant Orthopox Viral Vector Encoding Immunostimulatory Proteins for Cancer TreatmentJan 17, 2023Pending
18/566,077Vaccine Composition Comprising Encoded AdjuvantJun 20, 2022Pending
16/762,397Immunotherapeutic Combination for Treating CancerNov 6, 2018Abandoned
16/626,750Jul 12, 2018No status recorded
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited